These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

34 related articles for article (PubMed ID: 6683173)

  • 1. Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to V.
    Colleoni M; Sun Z; Price KN; Karlsson P; Forbes JF; Thürlimann B; Gianni L; Castiglione M; Gelber RD; Coates AS; Goldhirsch A
    J Clin Oncol; 2016 Mar; 34(9):927-35. PubMed ID: 26786933
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tamoxifen as the first targeted long-term adjuvant therapy for breast cancer.
    Jordan VC
    Endocr Relat Cancer; 2014 Jun; 21(3):R235-46. PubMed ID: 24659478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a century.
    Pagani O; Price KN; Gelber RD; Castiglione-Gertsch M; Holmberg SB; Lindtner J; Thürlimann B; Collins J; Fey MF; Coates AS; Goldhirsch A;
    Breast Cancer Res Treat; 2009 Sep; 117(2):319-24. PubMed ID: 19137426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality control of oestrogen receptor assays using frozen breast tumours.
    Wong SY; King G; Angus B; Tesdale A; Hawkins RA
    J Clin Pathol; 1986 Jun; 39(6):690-1. PubMed ID: 3722423
    [No Abstract]   [Full Text] [Related]  

  • 5. Quantification of oestrogen receptors in breast cancer: radiochemical assay on cytosols and cryostat sections compared with semiquantitative immunocytochemical analysis.
    Scheres HM; De Goeij AF; Rousch MJ; Hondius GG; Willebrand DD; Gijzen AH; Bosman FT
    J Clin Pathol; 1988 Jun; 41(6):623-32. PubMed ID: 3384997
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of continuous variables in breast cancer and head and neck cancer. Dependence on the cut-off level.
    Courdi A; Héry M; Chauvel P; Gioanni J; Namer M; Demard F
    Br J Cancer; 1988 Jul; 58(1):88-90. PubMed ID: 3166897
    [No Abstract]   [Full Text] [Related]  

  • 7. Steroid receptors in breast cancer: sources of inter-laboratory variation in dextran-charcoal assays.
    Thorpe SM
    Breast Cancer Res Treat; 1987; 9(3):175-89. PubMed ID: 2444291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality control in immunocytochemistry: experiences with the oestrogen receptor assay.
    Bosman FT; de Goeij AF; Rousch M
    J Clin Pathol; 1992 Feb; 45(2):120-4. PubMed ID: 1541691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality control of estrogen receptor assays in The Netherlands.
    Koenders T; Benraad TJ
    Breast Cancer Res Treat; 1983; 3(3):255-66. PubMed ID: 6367854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Quality control of the assay of receptors in human breast tumors].
    Pichon MF; Spyratos F; Milgrom E
    Pathol Biol (Paris); 1983 Nov; 31(9):741-5. PubMed ID: 6361671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reliability of steroid hormone receptor assays: an international study.
    Jordan VC; Zava DT; Eppenburger U; Kiser A; Sebek S; Dowdle E; Krozowski Z; Bennett RC; Funder J; Holdaway IM; Wittliff JL
    Eur J Cancer Clin Oncol; 1983 Mar; 19(3):357-63. PubMed ID: 6683173
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A quality control study to assess the inter-laboratory variability of routine estrogen and progesterone receptor assays.
    Zava DT; Wyler-von Ballmoos A; Goldhirsch A; Roos W; Takahashi A; Eppenberger U; Arrenbrecht S; Martz G; Losa G; Gomez F; Guelpa C
    Eur J Cancer Clin Oncol; 1982 Aug; 18(8):713-21. PubMed ID: 6891322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality control of clinical steroid receptor assays in Sweden.
    Sällström JF; Björkqvist K
    Recent Results Cancer Res; 1984; 91():119-21. PubMed ID: 6729207
    [No Abstract]   [Full Text] [Related]  

  • 14. Sources of improvement in between laboratory variation in estrogen and progestin receptor measurement using tissue samples during the Australian Quality Assurance Programme.
    Borjesson BW; Cauchi MN; Compton PJ; Elder PA; Foo TM; Gramacho C; Hähnel R; Harrison LC; Holdaway IM; Horsfall DJ
    Eur J Cancer Clin Oncol; 1989 Jul; 25(7):1087-93. PubMed ID: 2668010
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interlaboratory variability in the determination of estrogen receptor and progesterone receptor content in human breast tumors: quality control in Switzerland.
    Zava DT
    Recent Results Cancer Res; 1984; 91():122-8. PubMed ID: 6539493
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.